Sutro Biopharma Inc STRO:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:22 PM EDT
4.54UNCH (UNCH)
Volume
7,260
Close
4.54quote price arrow down-0.14 (-2.99%)
Volume
2,123,359
52 week range
2.01 - 6.13
Loading...
  • Open4.91
  • Day High4.98
  • Day Low4.46
  • Prev Close4.68
  • 52 Week High6.13
  • 52 Week High Date03/28/24
  • 52 Week Low2.01
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap371.346M
  • Shares Out81.79M
  • 10 Day Average Volume0.93M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change5.83

KEY STATS

  • Open4.91
  • Day High4.98
  • Day Low4.46
  • Prev Close4.68
  • 52 Week High6.13
  • 52 Week High Date03/28/24
  • 52 Week Low2.01
  • 52 Week Low Date11/13/23
  • Market Cap371.346M
  • Shares Out81.79M
  • 10 Day Average Volume0.93M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change5.83

RATIOS/PROFITABILITY

  • EPS (TTM)-1.89
  • P/E (TTM)-2.40
  • Fwd P/E (NTM)-1.28
  • EBITDA (TTM)-96.67M
  • ROE (TTM)-81.12%
  • Revenue (TTM)154.065M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-74.62%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sutro Biopharma Inc

Profile

MORE
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers...
Connie Matsui
Independent Chairman of the Board
William Newell J.D.
Chief Executive Officer, Director
Jane Chung
President, Chief Operating Officer
Edward Albini
Chief Financial Officer
Address
111 Oyster Point Blvd.
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
XERS
Xeris Biopharma Holdings Inc
2.00-0.05-2.44%
AGEN
Agenus Inc
11.12+0.42+3.93%
TRDA
Entrada Therapeutics Inc
15.70+0.38+2.48%
AKBA
Akebia Therapeutics Inc
1.13-0.02-1.74%
KPTI
Karyopharm Therapeutics Inc
1.12-0.02-1.75%